RESOURCES

Early safety insights can make or break a program. Discover how current industry thinking and practical strategies to help you apply secondary pharmacology more effectively, so you can make risk-informed decisions earlier.

For Translational Insights in Metabolic Discovery and Development

Accelerate innovation with complete kinase solutions

Neurotoxicity is a major cause of drug attrition with central nervous system (CNS) affected the most.

Class B GPCR Target Significance

WEE1 is a key regulator of the G2/M cell cycle checkpoint, inhibiting CDK1 to allow DNA repair before mitosis.

Our team partnered with an early-stage biotech on an A_2A receptor antagonist program initially targeting Parkinson’s disease.

Dose-response Relationships Across Clinically Relevant Human Targets

Assessing Fcγ receptor (FcγR) binding is an essential part of therapeutic antibody characterization, as these interactions influence a molecule’s effector function, safety profile, and mechanism of action.

Drug-induced Liver Injury (DILI) remains a major obstacle in drug development. Despite the use of various models, DILI continues to lead to drug attrition, post-market withdrawals, and safety warnings.

Clinical attrition of drug candidates is frequently driven by unforeseen safety liabilities, which are often associated with off-target pharmacological interactions.

The Adenosine A_2A Receptor (A_2AR) was selected as a representative GPCR to establish an integrated fragment‑based discovery workflow capable of screening fragments on the active receptor state.